Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TORCH: Erlotinib vs Chemotherapy in Advanced NSCLC
NCT00349219Phase 3Completed
- Sponsor
- National Cancer Institute
- Start
- Dec 2006
- Primary completion
- Dec 2011
- Modality
- Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of erlotinib in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoints: Overall Survival at 1 year and Progression Free Rate at 9 weeks. Started Dec 2006; status: completed.
02
Drugs
erlotinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT00349219.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00349219.